Healx will analyze proprietary Sanofi compound data using Healx’s AI-driven drug discovery platform to generate therapeutic rationale. November 13, 2024 07:00 AM Eastern Standard Time.

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe’s Atomico and Silicon Valley-based R42.. The ...

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...

Sanofi stock plunged on Friday, wiping 20 billion euros ($21 billion) off its market value, after it abandoned its 2025 profit target under a plan to list its consumer healthcare business to focus ...

Sanofi shares fell 0.4 percent in Wall Street trading on Monday, while Blueprint’s soared more than 26 percent to $127.79 a share. Hudson shocked investors in 2023 when his research and ...

Sanofi's Focus On Alzheimer's Disease The companies expect the deal to close in the third quarter. In addition to the $470 million, Vigil shareholders will receive a contingent value right, or CVR ...

Sanofi plans to phase in its own rebate model for 25 drugs — including anti-inflammatory injectable Dupixent, one of the top 10 drugs in global sales — early next year. It’s unclear how ...

Healx, an AI-enabled, clinical-stage biotech company specialising in rare diseases, today announced it will use a Sanofi compound to identify new disease indications using Healnet, Healx’s AI ...

Healx, a U.K. startup using AI to discover new drugs for rare diseases, has raised $47 million in a Series C round of funding co-led by Europe's Atomico and Silicon Valley-based R42. The company ...